Disposition of metformin: Variability due to polymorphisms of organic cation transporters

References

• Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–77.
   PubMed Web of Science ®Google Scholar
• Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2010;115:55–9.
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, . The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6.
   PubMed Web of Science ®Google Scholar
• Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, . Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120:2355–69.
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854–65.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
   PubMed Web of Science ®Google Scholar
• Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;2005(3): CD002966.
   Google Scholar
• IMS Health. IMS National Prescription Audit. 2010. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%2015%20Products%20by%20U%20S%20RXs.pdf.
   Google Scholar
• DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281–303.
   Google Scholar
• Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338:265–6.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010; (4):CD002967.
   Google Scholar
• FDA drug label, metformin hydrochloride tablets (Glucophage). 2008. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf.
   Google Scholar
• Zolk O, Solbach TF, Konig J, Fromm MF. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol. 2009;379:337–48.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360–72.
   PubMed Web of Science ®Google Scholar
• Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17:1100–9.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43.
   PubMed Web of Science ®Google Scholar
• Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, . Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes. 2007;56:2178–82.
   PubMed Web of Science ®Google Scholar
• Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metab Toxicol. 2008;4:529–44.
   PubMed Web of Science ®Google Scholar
• Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12:235–46.
   PubMed Web of Science ®Google Scholar
• Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16:195–202.
   PubMed Web of Science ®Google Scholar
• Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, . Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996;36:1012–21.
   PubMed Web of Science ®Google Scholar
• Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics. 2008;9:415–22.
   PubMed Web of Science ®Google Scholar
• Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos. 2008;36:1650–8.
   PubMed Web of Science ®Google Scholar
• Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24: 49–57.
   PubMed Web of Science ®Google Scholar
• Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002;302:510–5.
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, . Disposition of metformin (N, N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978;24:683–93.
   PubMed Web of Science ®Google Scholar
• Yin OQ, Tomlinson B, Chow MS. Variability in renal clearance of substrates for renal transporters in chinese subjects. J Clin Pharmacol. 2006;46:157–63.
   PubMedGoogle Scholar
• Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics. 2003;13:581–4.
   PubMedGoogle Scholar
• Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997;51:913–21.
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, . Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16:871–81.
   PubMed Web of Science ®Google Scholar
• Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22:255–9.
   PubMed Web of Science ®Google Scholar
• Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, . Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17:2127–35.
   PubMed Web of Science ®Google Scholar
• Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005;102:17923–8.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Wagenaar E, Van ES, Schinkel AH. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol. 2003;23:7902–8.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, . Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol. 2001;21:5471–7.
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, . Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117:1422–31.
   PubMed Web of Science ®Google Scholar
• Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol. 2003;63:844–8.
   PubMed Web of Science ®Google Scholar
• Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol. 2009;75:1280–6.
   PubMed Web of Science ®Google Scholar
• Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, . Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A. 2003;100:5902–7.
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, . Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50: 1227–40.
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, . The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86:299–306.
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, . Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58:1434–9.
   PubMed Web of Science ®Google Scholar
• Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, . Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007;52:117–22.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009; 9:242–7.
   PubMed Web of Science ®Google Scholar
• Gambineri A, Tomassoni F, Gasparini DI, Di Rocco A, Mantovani V, Pagotto U, . Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2010;95:E204–8.
   PubMed Web of Science ®Google Scholar
• Chen L, Takizawa M, Chen E, Schlessinger A, Choi JH, Segenthelar J, . Genetic polymorphisms in the organic cation transporter 1, OCT1, in Chinese and Japanese populations, exhibit altered function. J Pharmacol Exp Ther. 2010;335:42–50.
   PubMed Web of Science ®Google Scholar
• Ieiri I, Higuchi S. [Pharmacogenomics: inter-ethnic and intra-ethnic differences in pharmacokinetic and pharmacodynamic profiles of clinically relevant drugs]. Yakugaku Zasshi. 2009;129:231–5.
   Google Scholar
• Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, . The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–9.
   PubMed Web of Science ®Google Scholar
• Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, . Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002;12:395–405.
   PubMedGoogle Scholar
• Kang HJ, Song IS, Shin HJ, Kim WY, Lee CH, Shim JC, . Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos. 2007;35:667–75.
   PubMed Web of Science ®Google Scholar
• Zolk O, Solbach TF, König J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009;37:1312–8.
   PubMed Web of Science ®Google Scholar
• Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, . Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84:559–62.
   PubMed Web of Science ®Google Scholar
• Ha CJ, Wah YS, Kim MJ, Nguyen L, Ho LJ, Kang JO, . Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics. 2009;19:770–80.
   Google Scholar
• Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010; 298:F997–1005.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009;58:745–9.
   PubMed Web of Science ®Google Scholar
• Toyama K, Yonezawa A, Tsuda M, Masuda S, Yano I, Terada T, . Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet Genomics. 2010;20:135–8.
   PubMed Web of Science ®Google Scholar
• Kalow W, Endrenyi L, Tang B. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology. 1999;58:281–4.
   PubMed Web of Science ®Google Scholar
• Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, . Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab. 2008;93:792–800.
   PubMed Web of Science ®Google Scholar
• Lopez-Bermejo A, Diaz M, Moran E, de Zegher F, Ibanez L. A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. Diabetes Care. 2010;33:1544–8.
   PubMed Web of Science ®Google Scholar
• Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007;35:1956–62.
   PubMed Web of Science ®Google Scholar
• Sakata T, Anzai N, Shin HJ, Noshiro R, Hirata T, Yokoyama H, . Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun. 2004;313:789–93.
   PubMed Web of Science ®Google Scholar
• Itoda M, Saito Y, Maekawa K, Hichiya H, Komamura K, Kamakura S, . Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet. 2004;19:308–12.
   PubMedGoogle Scholar
• Li Q, Liu F, Zheng TS, Tang JL, Lu HJ, Jia WP. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol Sin. 2010;31:184–90.
   PubMed Web of Science ®Google Scholar
• Fukushima-Uesaka H, Maekawa K, Ozawa S, Komamura K, Ueno K, Shibakawa M, . Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet. 2004;19:239–44.
   PubMedGoogle Scholar
• Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, . Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008;83:273–80.
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18:637–45.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, . Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics. 2009;19:497–504.
   PubMed Web of Science ®Google Scholar
• Zolk O. Current understanding of the pharmacogenomics of metformin. Clin Pharmacol Ther. 2009;86:595–8.
   PubMed Web of Science ®Google Scholar